Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G, Tavarozzi R, Pini GM, Borra T, Gandolfo C, Zacchi G, Pietrasanta D, Monaco F, Zanni M, Lettieri M, Rivela P, Zallio F, Ladetto M. Catania G, et al. J Basic Clin Physiol Pharmacol. 2023 Apr 12;34(3):401-404. doi: 10.1515/jbcpp-2023-0051. eCollection 2023 May 1. J Basic Clin Physiol Pharmacol. 2023. PMID: 37040263
PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
Santi RM, Ceccarelli M, Catania G, Monagheddu C, Evangelista A, Bernocco E, Monaco F, Federico M, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Calabrese M, Levis A, Visco C, Contino L, Ciccone G, Ladetto M. Santi RM, et al. Among authors: catania g. Thromb Res. 2016 Apr;140 Suppl 1:S177. doi: 10.1016/S0049-3848(16)30136-0. Epub 2016 Apr 8. Thromb Res. 2016. PMID: 27161692
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.
Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C, Chiarenza A, Morelli F, Sportoletti P, Marasca R, Sapienza G, Cuccaro A, Murru R, Sanna A, Patti C, Angeletti I, Coscia M, Trentin L, Pietrasanta D, Innocenti I, Laurenti L. Fresa A, et al. Among authors: catania g. Blood Adv. 2022 Jul 12;6(13):3875-3878. doi: 10.1182/bloodadvances.2022006964. Blood Adv. 2022. PMID: 35789375 Free PMC article. No abstract available.
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice.
Tavarozzi R, Zacchi G, Pietrasanta D, Catania G, Castellino A, Monaco F, Gandolfo C, Rivela P, Sofia A, Schiena N, Bertassello C, Limberti G, Zallio F, Zanni M, Ladetto M. Tavarozzi R, et al. Among authors: catania g. Cancers (Basel). 2023 Nov 13;15(22):5397. doi: 10.3390/cancers15225397. Cancers (Basel). 2023. PMID: 38001657 Free PMC article. Review.
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Autore F, Innocenti I, Reda G, Visentin A, Vitale C, Piciocchi A, Fresa A, Leone MMA, Farina L, Quaresmini G, Baratè C, Giordano A, Ferrari A, Angeletti I, De Paolis MR, Malerba L, Chiurazzi F, Loseto G, Catania G, Sportoletti P, Scortechini I, Moia R, Gentile M, Rigolin GM, Mattiello V, Gattei V, Coscia M, Trentin L, Foà R, Cuneo A, Laurenti L. Autore F, et al. Among authors: catania g. Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1. Hematol Oncol. 2023. PMID: 37392141
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Martino EA, Mauro FR, Reda G, Laurenti L, Visentin A, Frustaci A, Vigna E, Pepe S, Catania G, Loseto G, Murru R, Chiarenza A, Sportoletti P, Del Principe MI, Laureana R, Coscia M, Galimberti S, Ferretti E, Zucchetto A, Bomben R, Polesel J, Tedeschi A, Rossi D, Trentin L, Neri A, Morabito F, Gattei V, Gentile M. Martino EA, et al. Among authors: catania g. Hematol Oncol. 2024 Jan;42(1):e3249. doi: 10.1002/hon.3249. Hematol Oncol. 2024. PMID: 38287529
270 results